Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association - PubMed (original) (raw)

Review

Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association

No authors listed. Am J Respir Crit Care Med. 1997 Aug.

Abstract

Diagnostic criteria of nontuberculous mycobacterial lung disease in HIV-seropositive and -seronegative hosts. The following criteria apply to symptomatic patients with infiltrate, nodular or cavitary disease, or a high resolution computed tomography scan that shows multifocal bronchiectasis and/or multiple small nodules. A. If three sputum/bronchial wash results are available from the previous 12 mo: 1. three positive cultures with negative AFB smear results or 2. two positive cultures and one positive AFB smear B. If only one bronchial wash is available: 1. positive culture with a 2+, 3+, or 4+ AFB smear or 2+, 3+, or 4+ growth on solid media C. If sputum/bronchial wash evaluations are nondiagnostic or another disease cannot be excluded: 1. transbronchial or lung biopsy yielding a NTM or 2. biopsy showing mycobacterial histopathologic features (granulomatous inflammation and/or AFB) and one or more sputums or bronchial washings are positive for an NTM even in low numbers.

Comments: these criteria fit best with M. avium complex, M. abscessus, and M. kansasii. Too little is known of other NTM to be certain how applicable these criteria will be. At least three respiratory samples should be evaluated from each patient. Other reasonable causes for the disease should be excluded. Expert consultation should be sought when diagnostic difficulties are encountered.

PubMed Disclaimer

Cited by

Disseminated Mycobacterium intracellulare Infection in an Immunocompetent Host.
Kim WY, Jang SJ, Ok T, Kim GU, Park HS, Leem J, Kang BH, Park SJ, Oh DK, Kang BJ, Lee BY, Ji WJ, Shim TS. Kim WY, et al. Tuberc Respir Dis (Seoul). 2012 May;72(5):452-6. doi: 10.4046/trd.2012.72.5.452. Epub 2012 May 29. Tuberc Respir Dis (Seoul). 2012. PMID: 23101011 Free PMC article.
Pulmonary Mycobacterium avium Complex With Adenocarcinoma of the Lung: A Case Report.
Mishra P, Kondisetti M, Patil A, Sarangdhar N. Mishra P, et al. Cureus. 2024 Aug 10;16(8):e66589. doi: 10.7759/cureus.66589. eCollection 2024 Aug. Cureus. 2024. PMID: 39252743 Free PMC article.
The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis.
Prasse A. Prasse A. Dtsch Arztebl Int. 2016 Aug 22;113(33-34):565-74. doi: 10.3238/arztebl.2016.0565. Dtsch Arztebl Int. 2016. PMID: 27598883 Free PMC article. Review.
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
Shen GH, Wu BD, Wu KM, Chen JH. Shen GH, et al. Antimicrob Agents Chemother. 2007 May;51(5):1849-51. doi: 10.1128/AAC.01551-06. Epub 2007 Mar 12. Antimicrob Agents Chemother. 2007. PMID: 17353252 Free PMC article.
Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.
Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Lounis N, et al. Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30. doi: 10.1128/AAC.45.11.3229-3230.2001. Antimicrob Agents Chemother. 2001. PMID: 11600387 Free PMC article.

Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association - PubMed (original) (raw)